Sai Ravi Pingali
Overview
Explore the profile of Sai Ravi Pingali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mai S, Hodges A, Chen H, Zhang J, Wang Y, Liu Y, et al.
Cancer Res
. 2023 Dec;
83(24):4047-4062.
PMID: 38098451
Significance: LILRB3 regulates differentiation and proliferation in acute myeloid leukemia and can be targeted with monoclonal antibodies and CAR T cells to suppress leukemia growth.
2.
Burns E, Wilson J, Mathur S, Kieser R, Gong Z, Hu C, et al.
Ann Hematol
. 2023 Jul;
102(10):2753-2763.
PMID: 37422592
Burkitt lymphoma (BL) is an extremely aggressive but curable subtype of non-Hodgkin lymphoma. While younger patients have excellent outcomes in response to aggressive chemoimmunotherapy, the rarity of this disease in...
3.
Chevli N, Margolis V, Haque W, Pingali S, Butler E, Teh B
Pract Radiat Oncol
. 2022 Oct;
13(1):e80-e93.
PMID: 36223873
Purpose: Nodal marginal zone lymphoma (NMZL) localized to a single lymphatic region (ie, stage I) is a relatively rare diagnosis. Current guidelines permit these patients to be either observed or...
4.
Lee A, Pingali S, Pinilla-Ibarz J, Atchison M, Koumenis C, Argon Y, et al.
Leukemia
. 2022 Aug;
36(10):2430-2442.
PMID: 36042317
Activation-induced cytidine deaminase (AID) has been implicated as both a positive and a negative factor in the progression of B cell chronic lymphocytic leukemia (CLL), but the role that it...
5.
Su P, Xiao L, Ye L, Wang Z, Xiong W, Wang Q, et al.
J Hematol Oncol
. 2022 May;
15(1):55.
PMID: 35526043
Lysophosphatidic acid (LPA) is a naturally occurring phospholipid that regulates cell proliferation, survival, and migration. However, its role on human multiple myeloma (MM) cells is largely unknown. In this study,...
6.
Gentille C, Sarfraz H, Joshi J, Randhawa J, Shah S, Pingali S
Cancer Rep (Hoboken)
. 2022 Mar;
5(7):e1581.
PMID: 35263030
Background: Relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in...
7.
Wang Q, Lin Z, Wang Z, Ye L, Xian M, Xiao L, et al.
Blood
. 2021 Aug;
139(1):59-72.
PMID: 34411225
Proteasome inhibitors (PIs) such as bortezomib (Btz) and carfilzomib (Cfz) are highly efficacious for patients with multiple myeloma (MM). However, relapses are frequent, and acquired resistance to PI treatment emerges...
8.
Mina S, Muhsen I, Burns E, Sarfraz H, Pingali S, Xu J, et al.
Turk J Haematol
. 2021 Jun;
38(3):218-221.
PMID: 34190655
Proteasome inhibitors (PIs) are an integral component of multiple myeloma therapies. Peripheral neuropathy (PN) is a well-knownconsequence of PIs, most frequently reported with earlier generations such as bortezomib (BTZ). There...
9.
Burns E, Gentille C, Trachtenberg B, Pingali S, Anand K
Diseases
. 2021 Apr;
9(1).
PMID: 33802788
Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of non-Hodgkin Lymphoma. As this treatment is...
10.
Youssef J, Zahiruddin F, Youssef G, Padmanabhan S, Ensor J, Pingali S, et al.
Ann Hematol
. 2021 Jan;
100(3):667-673.
PMID: 33439304
The severe pneumonia caused by the human coronavirus (hCoV)-SARS-CoV-2 has inflicted heavy casualties, especially among the elderly and those with co-morbid illnesses irrespective of their age. The high mortality in...